Myovant Sciences Ltd (MYOV) Expected to Post Earnings of -$0.47 Per Share

Share on StockTwits

Wall Street analysts predict that Myovant Sciences Ltd (NYSE:MYOV) will announce earnings of ($0.47) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Myovant Sciences’ earnings. Myovant Sciences posted earnings per share of ($0.39) during the same quarter last year, which would indicate a negative year-over-year growth rate of 20.5%. The company is scheduled to issue its next earnings results on Thursday, August 9th.

On average, analysts expect that Myovant Sciences will report full year earnings of ($1.58) per share for the current year, with EPS estimates ranging from ($1.95) to ($1.20). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Myovant Sciences.

Myovant Sciences (NYSE:MYOV) last announced its quarterly earnings results on Tuesday, June 12th. The company reported ($0.81) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.04).

Several analysts have recently weighed in on MYOV shares. Zacks Investment Research lowered Myovant Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, February 20th. ValuEngine raised Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th. Barclays lowered Myovant Sciences from an “overweight” rating to an “equal weight” rating and set a $18.00 price target on the stock. in a research report on Thursday, April 5th. Finally, Citigroup upped their price target on Myovant Sciences from $17.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday, April 25th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Myovant Sciences currently has a consensus rating of “Buy” and an average price target of $26.75.

In other news, Director Mark Altmeyer bought 3,500 shares of the company’s stock in a transaction on Saturday, November 17th. The shares were bought at an average cost of $13.38 per share, with a total value of $46,830.00. Following the transaction, the director now directly owns 3,500 shares in the company, valued at approximately $46,830. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Holdings Ltd. Dexxon bought 1,110,015 shares of the company’s stock in a transaction on Monday, April 2nd. The stock was purchased at an average cost of $20.27 per share, for a total transaction of $22,500,004.05. The disclosure for this purchase can be found here. Corporate insiders own 3.00% of the company’s stock.

A number of hedge funds have recently modified their holdings of MYOV. Swiss National Bank boosted its stake in shares of Myovant Sciences by 12.7% during the 1st quarter. Swiss National Bank now owns 28,300 shares of the company’s stock worth $602,000 after acquiring an additional 3,200 shares in the last quarter. Platinum Investment Management Ltd. bought a new stake in Myovant Sciences during the 1st quarter valued at approximately $1,152,000. Ardsley Advisory Partners bought a new stake in Myovant Sciences during the 4th quarter valued at approximately $1,272,000. Millennium Management LLC boosted its stake in Myovant Sciences by 54.3% during the 1st quarter. Millennium Management LLC now owns 106,868 shares of the company’s stock valued at $2,273,000 after purchasing an additional 37,602 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Myovant Sciences by 6.2% during the 1st quarter. JPMorgan Chase & Co. now owns 106,944 shares of the company’s stock valued at $2,275,000 after purchasing an additional 6,263 shares during the period. 18.46% of the stock is currently owned by institutional investors.

Myovant Sciences traded down $0.11, reaching $22.58, during trading hours on Friday, Marketbeat.com reports. The company’s stock had a trading volume of 2,334 shares, compared to its average volume of 48,982. The company has a quick ratio of 3.09, a current ratio of 3.09 and a debt-to-equity ratio of 1.16. The stock has a market cap of $1.47 billion, a PE ratio of -9.37 and a beta of -2.15. Myovant Sciences has a 1 year low of $9.92 and a 1 year high of $24.91.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand
Yankees Former Ace Ron Guidry Says Luis Severino Will Break His Records
Yankees Former Ace Ron Guidry Says Luis Severino Will Break His Records
Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Dodgers Getting Big Unexpected Lift from Three Players
Dodgers Getting Big Unexpected Lift from Three Players


Leave a Reply

 
© 2006-2018 BBNS.